GLP-1 risks in high-risk pregnancies: what OBs actually say

What did @the_highrisk_ob actually say?

This OB creator laid out three reasons GLP-1 medications like semaglutide and tirzepatide might be behind a wave of unintended pregnancies. First, delayed gastric emptying reduces oral contraceptive absorption. Second, weight loss lowers androgen levels from adipose tissue, restoring ovulation in women who weren't ovulating regularly. Third, patients feeling better about themselves are having more sex, sometimes without contraception. She also advises stopping these medications "two months before" a planned pregnancy.

The framing is casual and TikTok-friendly, but this is an actual OB-GYN making mechanistic claims. That raises the bar. Let's go through each one.

Does the science back this up?

Mostly yes, with important caveats on mechanism strength. The oral contraceptive absorption argument is the weakest of the three. The ovulation-restoration pathway is the most clinically supported. The behavioral explanation is plausible but effectively unverifiable.

On oral contraceptives: GLP-1 receptor agonists do delay gastric emptying, which theoretically slows drug absorption. But the evidence that this meaningfully reduces contraceptive efficacy is thin. A 2023 pharmacokinetic review (Buse et al., Diabetes Care) noted that semaglutide's effect on gastric emptying is most pronounced early in treatment and diminishes over time. There are no robust clinical trials directly linking GLP-1 use to contraceptive failure. The FDA label for Wegovy does mention the theoretical interaction, but "theoretical" is doing a lot of work here.

On ovulation restoration: this is well-grounded. Adipose tissue converts androgens to estrogens in a disruptive hormonal loop, and excess androgens suppress ovulation, particularly in women with polycystic ovary syndrome. Weight loss of 5-10% has been shown to restore ovulatory function in anovulatory obese women (Kiddy et al., 1992, Clinical Endocrinology). GLP-1s achieving that weight loss would plausibly have the same effect.

What did they get wrong (or right)?

The androgen-ovulation explanation is largely accurate, but the creator oversimplifies the mechanism. She says adipose tissue contains "androgens" that "inhibit ovulation," but the more precise mechanism is that adipose tissue expresses aromatase, which converts androgens to estrogens, creating a disruptive feedback loop that suppresses LH surge and ovulation. It is not just about androgen levels directly. The distinction matters clinically, especially for PCOS patients where the picture is more complex.

The gastric emptying claim is the one I'd push back on hardest. Saying women "are not getting as much efficacy from their pill" as a confident statement overstates what the data actually shows. A 2022 analysis by researchers at Novo Nordisk found that semaglutide had minimal effect on the pharmacokinetics of a combined oral contraceptive in a small trial (DeVries et al., 2022). The effect was not clinically significant in that study.

The two-month washout recommendation before pregnancy is consistent with current clinical guidance. Semaglutide's half-life is approximately one week, so two months provides a reasonable clearance buffer given the lack of human safety data in early pregnancy.

What should you actually know?

If you are on a GLP-1 medication and sexually active, this video is raising a genuinely important clinical point, even if some of the mechanistic details are imprecise. The practical bottom line: do not assume your current contraceptive situation is unchanged once you start these medications or start losing weight significantly.

Women with obesity-related anovulation, including many with PCOS, may resume ovulating after significant weight loss, whether that loss came from GLP-1 drugs or any other intervention. That is a real phenomenon with real reproductive consequences. If you were previously told you were unlikely to conceive due to irregular ovulation, that assessment may no longer apply.

On contraception specifically, if you rely on oral contraceptives and are starting a GLP-1 medication, it is reasonable to discuss backup contraception with your provider, not because the data is definitive, but because the theoretical risk exists and the consequences of an unintended pregnancy are significant. Non-oral methods like IUDs or implants sidestep the absorption question entirely.

The two-month pre-conception stopping point is practical guidance, but there is no human teratogenicity data yet, just animal studies showing fetal harm at high doses. That absence of data is not reassurance.